ZKB BARRIER REVERSE CONVERTIBLE ON WORST OF - PHILIPS/BAYER/NOVARTIS N/SANOFI Share Price

Certificat

Z09EPZ

CH1329124007

Delayed Swiss Exchange 16:20:00 17/05/2024 BST
106.5 EUR +0.02% Intraday chart for ZKB BARRIER REVERSE CONVERTIBLE ON WORST OF - PHILIPS/BAYER/NOVARTIS N/SANOFI
Current month+2.06%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
17/05/24 106.5 +0.02%
15/05/24 106.5 +0.08%
14/05/24 106.4 +0.10%
13/05/24 106.3 +0.58%

Delayed Quote Swiss Exchange

Last update May 17, 2024 at 04:20 pm

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying NOVARTIS AG
Issuer ZKB
Z09EPZ
ISINCH1329124007
Date issued 18/04/2024
Strike 84.52 CHF
Maturity 22/04/2025 (338 Days)
Parity 1 : 1
Emission price 100
Emission volume N/A
Settlement both
Currency EUR

Technical Indicators

Highest since issue 106.5
Lowest since issue 101
Spread 5
Spread %0.47%

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
-
More about the company

Ratings for Novartis AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Novartis AG

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
102.9 USD
Average target price
107.9 USD
Spread / Average Target
+4.93%
Consensus
  1. Stock Market
  2. Certificates
  3. Z09EPZ Certificat